Deutsche Bank Downgrades BioMarin Pharmaceutical Inc. (BMRN) to Hold; Risk/Reward Into Phase 3 GALNS
Tweet Send to a Friend
Deutsche Bank downgraded BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from Buy to Hold with a new price target of $45.00.
This article: 142 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This article: 142 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
